Mena Boules, MD: The Challenge in Finding a Treatment for EoE


There currently is not an approved treatment for EoE by the US Food and Drug Administration.

There is currently no US Food and Drug Administration (FDA) approved treatment for eosinophilic esophagitis (EoE), leaving doctors, patients, and families to make decisions on how to best alleviate the symptoms associated with the disease, mainly dysphagia.

But help could soon be on the way for this patient population.

In an interview with HCPLive®, Mena Boules, MD, Executive Medical Director, Gastroenterology, US Medical Affairs at Takeda Pharmaceuticals, talked about why he is hopeful that patients with EoE may soon have multiple treatment options to treat the disease.

Boules said there has a push to develop treatments for the disease in recent years, mainly due to increased awareness of the chronic condition.

“I think there are a number of advances that are currently happening in the field of EoE, there certainly is a lot of attention because of how chronic and debilitating the disease has been over the years,” Boules said. “More and more people are becoming aware of it.”

Boules said clinicians often have to make plans with patients as to what works best for them based on efficacy and safety data in absence of an FDA approved therapy.

He also said the challenge in finding a treatment is because it is a disease that affects the histologic aspects and the structure of the esophagus and is a disease that encompasses a variable of symptoms.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.